Hypera S A : Notice to the Market - Acquisition of Equity Interest in Consulta Remédios
April 16, 2021 at 08:25 pm
Share
HYPERA S.A.
A Publicly-Held Corporation
CNPJ No. 02.932.074/0001-91
NIRE 35.300.353.251
Code CVM No. 21431
NOTICE TO THE MARKET
HYPERA S.A. ("Company" or "Hypera Pharma"), in compliance with the provisions of Article 157, paragraph 4, of Law No. 6,404, of December 15, 1976, as amended, and of the Brazilian Securities Commission ("CVM") Rule No. 358, of January 3, 2002, as amended, informs its shareholders and the market in general that it has entered into an investment agreement for the acquisition of a minority equity interest in Consulta Remédios, of 22.5% of its capital stock, with the possibility of increasing such minority interest, being the conclusion of the transaction subject to the compliance with certain conditions precedent.
Consulta Remédios ("www.consultaremedios.com.br") is the largest platform for accessing and consulting pharmaceutical products information in Brazil and the 5th largest pharmaceutical portal in the world in number of visitors. With presence in all regions of the country, Consulta Remédios operates in partnership with large and medium-sized pharmaceutical retail chains, and today has approximately 1 million unique visitors daily.
This is the second investment of Hypera Ventures, a corporate venture capital initiative that seeks to invest in startups linked to the health and wellness sector that have synergies with Hypera Pharma's business. This movement is in line with the Company's strategic objective of accelerating its investments in technology and digital platforms in order to continuously increase its proximity to its end consumers, understanding their consumption habits with the purpose of boosting sales and promoting quality health to the Brazilian population.
São Paulo, April 16, 2021.
HYPERA S.A.
Adalmario Ghovatto Satheler do Couto
Investor Relations Officer
Attachments
Original document
Permalink
Disclaimer
Hypera SA published this content on 17 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 April 2021 00:24:06 UTC.
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.